Image-guided irreversible electroporation directed CAR T-cell delivery to solid tumors

图像引导不可逆电穿孔引导 CAR T 细胞递送至实体瘤

基本信息

  • 批准号:
    9764302
  • 负责人:
  • 金额:
    $ 39.85万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2018
  • 资助国家:
    美国
  • 起止时间:
    2018-08-15 至 2023-07-31
  • 项目状态:
    已结题

项目摘要

PROJECT ABSTRACT Tumor infiltrating lymphocytes (TILs) can significantly increase the success of immunotherapy. Solid tumors present barriers to TIL penetration and function. Strategies to increase TILs and their function are challenged by the inability to direct the delivery of T cells into solid tumors and a lack of techniques to predict their uptake. Through this proposal, we will develop the use of image-guided irreversible electroporation (IRE) as a novel approach to promote TILs in solid tumors. IRE is clinically used for the treatment of solid tumors by applying microsecond long electric pulses that kill cells through rapid permeabilization of the cell membrane. A unique feature of IRE is that, while killing cells, it spares the extracellular matrix and blood vessels within the treatment region, which is ideal for stimulating local inflammation and promoting TILs. We will investigate our proposed strategy in translational mouse models and in patients with malignant pleural mesothelioma (MPM), which is a solid tumor where a higher ratio of cytotoxic TIL to immunosuppressor cells has already been shown to increase patient survival. In our experiments, we will use chimeric antigen receptor (CAR) T cells that are genetically modified to recognize mesothelin, a cell surface antigen that is overexpressed on mesothelioma cancer cells. Based on prior work by the PIs' team, we rationalize that cell death from IRE: (i) can be imaged using intra-procedural FDG-PET; (ii) can generate an intratumoral chemokine gradient that promotes TILs; and (iii) therefore, FDG-PET guided IRE can serve as a surrogate to both map and drive tumor-targeted CAR T-cell delivery. Furthermore, our strategy of IRE-directed CAR T-cell infiltration can be repeated using electric pulse parameters designed to be cancer cell-targeted/TIL-sparing, thereby augmenting immunotherapeutic efficacy. The long-term goal of our work is to develop image-guided IRE as a platform for predictable, reproducible, and controllable delivery of CAR T cells and other cellular anticancer therapies to solid tumors. In Aim 1, we will create an integrated tumor immune microenvironment map (iTIMM) combining FDG-PET imaging, computer simulations, and quantitative multiplex immunofluorescence histology to develop a tool that will determine T- cell localization in solid tumors treated with IRE. iTIMM will then be used to develop a clinically relevant protocol that, in combination of intravenous administration of T cells, will be used to increase TILs. In Aim 2, we will use dual imaging with PET (cancer cells) and bioluminescence imaging (T cells) to validate IRE pulse parameters to selectively enrich and increase functional CAR T cells within MPM. In Aim 3, we will perform a pilot clinical trial using PET-guided transthoracic IRE of MPM prior to resection to validate the concept of iTIMM and its effect on TILs. The modulation of the tumor microenvironment with image-guided IRE to map and localize T-cell delivery, promoting CAR T cell function, and translational validation of iTIMM presents innovative rational combinations of clinically used techniques and is an ambitious attempt to address a key challenge to solid tumor immunotherapy.
项目摘要 肿瘤浸润性淋巴细胞(TILs)可显著提高免疫治疗的成功率。实体瘤 存在阻碍TIL渗透和发挥作用的障碍。增加TILs的策略及其功能面临挑战 这是由于无法直接将T细胞输送到实体瘤中,以及缺乏预测其摄取的技术。 通过这项提议,我们将发展图像引导不可逆电穿孔(Ire)作为一种新颖的应用 在实体瘤中促进TIL的方法。IRE临床上用于治疗实体瘤,通过应用 微秒长的电脉冲,通过细胞膜的快速渗透杀死细胞。独一无二的 IRE的特点是,在杀死细胞的同时,它保留了治疗过程中的细胞外基质和血管 这是刺激局部炎症和促进TIL的理想选择。我们将调查我们提出的 翻译小鼠模型和恶性胸膜间皮瘤(MPM)患者的策略 细胞毒性TIL与免疫抑制细胞的比率较高的实体瘤已被证明 提高患者存活率。在我们的实验中,我们将使用嵌合抗原受体(CAR)T细胞 基因修饰以识别间皮瘤上过度表达的细胞表面抗原--间皮蛋白 癌细胞。基于PI团队之前的工作,我们合理地认为IRE导致的细胞死亡:(I)可以成像 使用程序内FDG-PET;(Ii)可以产生促进TIL的肿瘤内趋化因子梯度;以及 因此,FDG-PET引导的IRE可以作为映射和驱动肿瘤靶向CAR T细胞的替代物 送货。此外,我们的IRE定向CAR T细胞渗透策略可以使用电脉冲重复 参数设计为癌细胞靶向/保留TIL,从而增强免疫治疗效果。 我们工作的长期目标是开发以图像为导向的IRE作为一个平台,以实现可预测、可重现和 可控地将CAR T细胞和其他细胞抗癌疗法输送到实体肿瘤。在目标1中,我们将 创建结合FDG-PET成像和计算机的集成肿瘤免疫微环境图(ITIMM) 模拟,和定量多重免疫荧光组织学,以开发一种工具,将确定T- IRE治疗实体瘤的细胞定位。然后,iTIMM将被用于开发一种临床相关的 与静脉注射T细胞相结合的方案,将用于增加TIL。在目标2中,我们 将使用PET(癌细胞)和生物发光成像(T细胞)的双重成像来验证IRE脉冲 参数,以选择性地丰富和增加MPM内的功能CAR T细胞。在目标3中,我们将执行一项 PET引导下经胸MPM术的初步临床试验验证iTIMM概念 及其对TIL的影响。图像导引IRE对肿瘤微环境的调节 本地化T细胞交付,促进CAR T细胞功能,iTIMM的翻译验证呈现创新 临床使用技术的合理组合,是解决以下关键挑战的雄心勃勃的尝试 实体瘤免疫治疗。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Prasad S. Adusumilli其他文献

臨床病期I期の肺腺癌における組織亜型による経時的再発ハザードの層別化の有用性
根据临床 I 期肺腺癌的组织学亚型随时间推移对复发风险进行分层的实用性
  • DOI:
  • 发表时间:
    2021
  • 期刊:
  • 影响因子:
    0
  • 作者:
    高橋 祐介;Prasad S. Adusumilli
  • 通讯作者:
    Prasad S. Adusumilli
原核生物由来ナトリウムチャネルに創出された二価カチオ ンによる電流阻害の分子機構
原核钠通道中产生的二价阳离子抑制电流的分子机制
  • DOI:
  • 发表时间:
    2023
  • 期刊:
  • 影响因子:
    0
  • 作者:
    高橋 祐介;Prasad S. Adusumilli;入江 克雅
  • 通讯作者:
    入江 克雅
Therapeutic effect of oncolytic herpes simplex virus (NV1066) on radioresistant head and neck squamous cell carcinoma
  • DOI:
    10.1016/j.jamcollsurg.2005.06.146
  • 发表时间:
    2005-09-01
  • 期刊:
  • 影响因子:
  • 作者:
    Se-Heon Kim;Richard J. Wong;David Eisenberg;Yun Shin Chun;Zhenkun Yu;Prasad S. Adusumilli;Jatin P. Shah;Yuman Fong
  • 通讯作者:
    Yuman Fong
Commission on Cancer Standards for Lymph Node Sampling and Oncologic Outcomes After Lung Resection
癌症委员会关于肺切除术后淋巴结采样及肿瘤学预后的标准
  • DOI:
    10.1016/j.athoracsur.2024.09.009
  • 发表时间:
    2025-02-01
  • 期刊:
  • 影响因子:
    3.900
  • 作者:
    Benjamin J. Resio;Kay See Tan;Matthew Skovgard;Joe Dycoco;Prasad S. Adusumilli;Manjit S. Bains;Matthew J. Bott;Robert J. Downey;Katherine D. Gray;James Huang;Daniela Molena;Bernard J. Park;Valerie W. Rusch;Smita Sihag;Gaetano Rocco;David R. Jones;James M. Isbell
  • 通讯作者:
    James M. Isbell
The Emerging Role of Immunotherapy in Resectable Non-Small Cell Lung Cancer
  • DOI:
    10.1016/j.athoracsur.2024.01.024
  • 发表时间:
    2024-07-01
  • 期刊:
  • 影响因子:
  • 作者:
    Elizabeth G. Dunne;Cameron N. Fick;James M. Isbell;Jamie E. Chaft;Nasser Altorki;Bernard J. Park;Jonathan Spicer;Patrick M. Forde;Daniel Gomez;Puneeth Iyengar;David H. Harpole;Thomas E. Stinchcombe;Moishe Liberman;Matthew J. Bott;Prasad S. Adusumilli;James Huang;Gaetano Rocco;David R. Jones
  • 通讯作者:
    David R. Jones

Prasad S. Adusumilli的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Prasad S. Adusumilli', 18)}}的其他基金

A phase I/II combination immunotherapy clinical trial: mesothelin-targeted chimeric antigen receptor T cells and checkpoint blockade agent in pleural mesothelioma
I/II期联合免疫治疗临床试验:间皮素靶向嵌合抗原受体T细胞和检查点阻断剂治疗胸膜间皮瘤
  • 批准号:
    10208821
  • 财政年份:
    2019
  • 资助金额:
    $ 39.85万
  • 项目类别:
A phase I/II combination immunotherapy clinical trial: mesothelin-targeted chimeric antigen receptor T cells and checkpoint blockade agent in pleural mesothelioma
I/II期联合免疫治疗临床试验:间皮素靶向嵌合抗原受体T细胞和检查点阻断剂治疗胸膜间皮瘤
  • 批准号:
    10658882
  • 财政年份:
    2019
  • 资助金额:
    $ 39.85万
  • 项目类别:
A phase I/II combination immunotherapy clinical trial: mesothelin-targeted chimeric antigen receptor T cells and checkpoint blockade agent in pleural mesothelioma
I/II期联合免疫治疗临床试验:间皮素靶向嵌合抗原受体T细胞和检查点阻断剂治疗胸膜间皮瘤
  • 批准号:
    10445296
  • 财政年份:
    2019
  • 资助金额:
    $ 39.85万
  • 项目类别:
Image-guided irreversible electroporation directed CAR T-cell delivery to solid tumors
图像引导不可逆电穿孔引导 CAR T 细胞递送至实体瘤
  • 批准号:
    10221646
  • 财政年份:
    2018
  • 资助金额:
    $ 39.85万
  • 项目类别:
Image-guided irreversible electroporation directed CAR T-cell delivery to solid tumors
图像引导不可逆电穿孔引导 CAR T 细胞递送至实体瘤
  • 批准号:
    10478835
  • 财政年份:
    2018
  • 资助金额:
    $ 39.85万
  • 项目类别:
Imaging the efficacy of TRAIL-enhanced cancer immunotherapy
TRAIL 增强癌症免疫疗法的功效成像
  • 批准号:
    9387986
  • 财政年份:
    2017
  • 资助金额:
    $ 39.85万
  • 项目类别:
Mesothelin as a biomarker for clinical management of esophageal adenocarcinoma
间皮素作为食管腺癌临床治疗的生物标志物
  • 批准号:
    8508213
  • 财政年份:
    2012
  • 资助金额:
    $ 39.85万
  • 项目类别:
Mesothelin as a biomarker for clinical management of esophageal adenocarcinoma
间皮素作为食管腺癌临床治疗的生物标志物
  • 批准号:
    8386226
  • 财政年份:
    2012
  • 资助金额:
    $ 39.85万
  • 项目类别:
Validation of a risk model for stage I lung adenocarcinoma
I 期肺腺癌风险模型的验证
  • 批准号:
    8386244
  • 财政年份:
    2012
  • 资助金额:
    $ 39.85万
  • 项目类别:
Validation of a risk model for stage I lung adenocarcinoma
I 期肺腺癌风险模型的验证
  • 批准号:
    8508212
  • 财政年份:
    2012
  • 资助金额:
    $ 39.85万
  • 项目类别:

相似海外基金

心房細動に対するPulsed Field Ablationの組織創傷治癒過程を明らかにする網羅的研究
阐明房颤脉冲场消融组织伤口愈合过程的综合研究
  • 批准号:
    24K11201
  • 财政年份:
    2024
  • 资助金额:
    $ 39.85万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Targeted ablation of cerebral atherosclerosis using supramolecular self-assembly
利用超分子自组装靶向消融脑动脉粥样硬化
  • 批准号:
    24K21101
  • 财政年份:
    2024
  • 资助金额:
    $ 39.85万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
遅延造影心臓MRIによる心房細動Ablation冷却効果の比較:28 vs. 31 mm Cryoballoon
使用延迟对比增强心脏 MRI 比较房颤消融冷却效果:28 毫米与 31 毫米 Cryoballoon
  • 批准号:
    24K11281
  • 财政年份:
    2024
  • 资助金额:
    $ 39.85万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
CAREER: Heat Penetration Depth and Direction Control with Closed-Loop Device for Precision Ablation
职业:利用闭环装置控制热穿透深度和方向,实现精确烧蚀
  • 批准号:
    2338890
  • 财政年份:
    2024
  • 资助金额:
    $ 39.85万
  • 项目类别:
    Continuing Grant
Collaborative Research: RUI: Frontal Ablation Processes on Lake-terminating Glaciers and their Role in Glacier Change
合作研究:RUI:湖终止冰川的锋面消融过程及其在冰川变化中的作用
  • 批准号:
    2334777
  • 财政年份:
    2024
  • 资助金额:
    $ 39.85万
  • 项目类别:
    Continuing Grant
Collaborative Research: RUI: Frontal Ablation Processes on Lake-terminating Glaciers and their Role in Glacier Change
合作研究:RUI:湖终止冰川的锋面消融过程及其在冰川变化中的作用
  • 批准号:
    2334775
  • 财政年份:
    2024
  • 资助金额:
    $ 39.85万
  • 项目类别:
    Continuing Grant
InSPACE-VT_Development and Validation of Virtual Pace Mapping to Guide Catheter Ablation of Ventricular Tachycardia
InSPACE-VT_虚拟起搏测绘的开发和验证以指导室性心动过速导管消融
  • 批准号:
    EP/Z001145/1
  • 财政年份:
    2024
  • 资助金额:
    $ 39.85万
  • 项目类别:
    Fellowship
Collaborative Research: RUI: Frontal Ablation Processes on Lake-terminating Glaciers and their Role in Glacier Change
合作研究:RUI:湖终止冰川的锋面消融过程及其在冰川变化中的作用
  • 批准号:
    2334776
  • 财政年份:
    2024
  • 资助金额:
    $ 39.85万
  • 项目类别:
    Continuing Grant
MRI: Acquisition of a Laser Ablation - Inductively Coupled Plasma - Triple Quadrupole - Mass Spectrometer (LA-ICP-QQQ-MS) System For Research and Education
MRI:获取用于研究和教育的激光烧蚀 - 电感耦合等离子体 - 三重四极杆 - 质谱仪 (LA-ICP-MS/MS) 系统
  • 批准号:
    2320040
  • 财政年份:
    2023
  • 资助金额:
    $ 39.85万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了